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Abstract
Most behavioral, physiological and cellular effects of the neurotransmitter
dopamine require concomitant activation of both D1 and D2 receptors, a phenomenon
referred to as D1/D2 synergism. Since D1 and D2 receptors are located mostly on
separate neurons, and since D1/D2 synergism occurs in the absence of action potentials,
we have suggested that electrotonic coupling via gap junctions plays an important role in
this phenomenon. A major constituent of gap junctions is connexin36 (Cx36), a protein
that is abundant in neurons. The role Cx36 in D1/D2 synergism, as manifested
behaviorally, was studied here in mice genetically engineered to express normal, reduced,
or undetectable amounts of this protein. The results show that D1/D2 synergism and its
breakdown were not affected by the presence or absence of Cx36. Unexpectedly, it was
observed that the absence of Cx36 leads to resistance to the cataleptic effects of reserpine
in a gene dosage-dependent manner.
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Introduction

Gap junction channels are intercellular channels that allow the passage of ions and small
molecules (~1kDa) between neighboring cells. These channels are dynamic, opening and
closing in response to various intracellular and extracellular signals. Each hemichannel, called a
connexon, is made up of six proteins called connexins. These connexins are synthesized in
either the endoplasmic reticulum or the trans-Golgi network and from here they travel via
microtubules to the plasma membrane. Once embedded in the plasma membrane connexins
come together to form a connexon and two connexons that lie across from each other in adjacent
cells form a gap junction (Ebihara, 2003). Initially gap junctions were thought to exist only in
invertebrates, but since their discovery over 30 years ago, and with advances in technology, gap
junctions are now known to be present in the mammalian central nervous system (Bennett,
1997).
To date there are over 20 different types of connexins found in mammals (Willecke et al.,
2002). They are named for their predicted molecular weights; for example, connexin 36 (Cx36)
has a mass of ~ 36 kDa. Most cells can express any number of connexons, and these connexons
can be homomeric or heteromeric. However, Cx36, our connexin of interest, can only function
as a homomeric channel (Al-Ubaidi, White, Ripps, Poras, Avner, Gomes, et al. 2000).

Location of Cx36 in the Brain
Using in situ hybridization Condorelli and colleagues (Condorelli, Belluardo, SalinaroTrovato, & Mudo, 2000) analyzed the distribution of Cx36 mRNA in the rat central nervous
system. They found that Cx36 is present in the lamina of the gray matter of the spinal cord and
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in the dorsal root ganglia, the inferior olivary complex, cerebellum, hypothalamus, thalamus,
hippocampus, cerebral cortex, olfactory bulb, retina and the basal ganglia.
We are interested in how the presence or absence of Cx36 affects the basal ganglia and in
particular if the Cx36 gap junction has a role in the intriguing phenomenon whereby D1- and D2type dopamine (DA) receptors interact synergistically.

Basal Ganglia
The basal ganglia are involved in many neuronal pathways that include movement,
attention, affect, and learning and memory (Ring & Serra-Mestres, 2002). The basal ganglia
include the striatum, which is composed of the caudate and putamen nuclei and the nucleus
accumbens. (In rodents and other animals, the caudate and putamen are not distinct structures
and are thus referred to as the caudate-putamen; CPu.) The striatum receives input from multiple
cortical areas and projects through the globus pallidus and the substantia nigra pars reticulata
(SNr) to the thalamus and, ultimately, back to the cortex. In addition, the striatum receives dense
dopaminergic input from the substantia nigra pars compacta (SNc).
The striatum is the largest structure in the basal ganglia and can be functionally and
anatomically divided into dorsal and ventral areas. The dorsal striatum (caudate and putamen)
receives inputs from the association areas of the neocortex and the sensorimotor cortex. The
ventral striatum (nucleus accumbens) receives input from the orbitofrontal cortex and other
limbic cortical areas (Herrero, Barcia, & Navarro, 2002). Efferent striatal neurons consist
mainly of GABAergic medium spiny neurons, which make up 90-95% of the striatal neuron
population; the remaining 5-10% are local interneurons that are GABAergic or cholinergic
(Gerfen, 1992). Efferent projections from the dorsal striatum are divided into two pathways, the
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(a) direct, and (b) indirect pathways. Direct pathway neurons contain predominantly DA D1
receptors and synapse mainly in the SNr. Indirect pathway neurons leave the striatum and travel
to the globus pallidus; from there the pathway continues to the subthalamic nucleus and then to
the SNr. Striatopallidal neurons of this pathway contain predominantly DA D2 receptors. The
movement disorder Parkinson’s disease results from increased activity in the indirect pathway
and decreased activity in direct pathway due to the loss of DA input (Herrero et al., 2002).

Dopamine Receptors
DA receptors belong to a group of signal transduction proteins called guanine nucleotidebinding proteins (G-proteins). DA receptors can be divided into two groups: D1 and D2
receptors. The D1 group consists of D1 and D5 receptors. D1 receptors are located in the SNr,
caudate, putamen, nucleus accumbens, and olfactory tubercle. D5 receptors are located in the
hypothalamus, thalamus, and hippocampus (Sibley and Monsma, 1992). D1 receptors greatly
outnumber D5 receptors.
The D2 group consists of D2, D3, and D4 receptors. D2 receptors are located in the SNc,
caudate, putamen, nucleus accumbens, and olfactory tubercle and bulb. D3 receptors are located
in the nucleus accumbens and cerebellum and D4 receptors are located in the medulla, midbrain,
hypothalamus, thalamus, amygdala, and olfactory bulbs (Sibley and Monsma, 1992). D2
receptors greatly outnumber D3 and D4 receptors except in nucleus accumbens where D3
receptors are plentiful.
The main difference between the D1- and D2-like receptors is in their signal transduction
pathways. When DA binds with a D1-type receptor this leads to an increase in adenylyl cyclase
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activity and an increase in cAMP production. When DA binds to a D2-type receptor this leads to
a decrease in adenylyl cyclase activity (Kebabian and Calne, 1979).

Dopamine Pathways
DA constitutes about 80% of the total amount of catecholamines in the brain. Yet, the
total number of DA cells present in the brain is very small when compared with the total number
of cells present in the brain. DA nerve cells are found mainly in the midbrain, hypothalamus,
and olfactory bulbs and from these areas there are both ascending and descending projection
pathways (Roth, Wolf, and Deutch, 1987).
The mesostriatal system arises from neurons in the SNc (A9), ventral tegmental area
(A10), and the retrorubral nucleus (A8). The dorsal projections from this system give rise to the
nigrostriatal pathway. DA fibers that originate in the SNc project to the caudate, putamen, and to
a much lesser degree to the globus pallidus. These neurons show numerous branching in the
striatum and this pathway is very important in motor control. The loss of neurons in this
pathway leads to Parkinson’s disease (Fuxe, Aganti, Kalia, Goldstein, Andersson, & Harfstrand,
1985).
The ventral projections from the mesostriatal system give rise to the mesocorticolimbic
pathway. This pathway arises from the A10 group of cells, and some of the A8 and A9 cells, and
projects to the nucleus accumbens, septum, amygdala, hippocampus, nucleus of the diagonal
band, anterior olfactory nucleus, and limbic cortical areas. This pathway is believed to be
hyperactive in schizophrenia (Fuxe et al., 1985). Also, the DA projections to the nucleus
accumbens have been linked to the addictive properties of drugs of abuse (Bozarth and Wise,
1983).
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D1/D2 Synergism
D1- and D2-type receptors can be activated or inhibited by a variety of drug treatments
and the effects of these drugs can be seen in motor behavior. In normal rats and mice, the
administration of the mixed D1/D2 agonist apomorphine leads to locomotion at low to moderate
doses and stereotypical motor behavior at higher doses. Typically, the rat or mouse will
demonstrate continuous sniffing, licking, biting or gnawing and they will stand upright against a
vertical grid (Braun and Chase, 1986).
Many of the behaviors that are controlled by DA are only observed by the activation of
both D1 and D2 receptors. This is known as D1/D2 synergism. Both in vivo and in vitro
research confirm this phenomenon. Lewis, Widerlov, Knight, Kilts, & Mailman (1983) showed
that either a selective D1 or a selective D2 antagonist could block locomotion and motor
stereotypy elicited by the nonselective DA agonist apomorphine. Research by Walters,
Bergstrom, Carlson, Chase, & Braun (1987) showed that there has to be concomitant stimulation
of both D1 and D2 receptors in order to see a disinhibition of globus pallidus neurons and an
inhibition of caudate-putamen neurons. Importantly, Walters et al. (1987) also showed that
endogenous DA acting at D1 receptors is sufficient to synergize with an exogenous D2 agonist.
Thus, it is crucial in studies of D1/D2 synergism to control for endogenous DA. In doing this,
LaHoste and Marshall (1992) showed that, in normal rodents, the behavioral effects of a
selective DA agonist can be blocked by the heterotypic antagonist.
D1/D2 synergism can also be seen in the DA-stimulated expression of the immediateearly gene c-fos in striatal neurons. When D1 and D2 agonists are administered together this
results in the expression of c-fos in the striatum (LaHoste, Yu, & Marshall, 1993). Furthermore,
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either a selective D1 or a selective D2 antagonist can block the striatal c-fos response to
amphetamine or cocaine (Graybiel, Mortalla, & Robertson, 1990).
Breakdown in D1/D2 Synergism
Under normal conditions co-stimulation of D1 and D2 receptors is necessary for motor
behavior in rats and mice as described above. However, once DA has been depleted from the
striatum this no longer holds true. Denervation of the nigrostriatal pathway by 6hydroxydopamine (6-OHDA) or the administration of the monoamine depleting agent reserpine
causes a breakdown in D1/D2 synergism (Rouillard and Bedard, 1988).
In 24-h reserpine (5mg/kg) treated mice, the sole stimulation of the D1 receptor by SKF
38393 restored the motor behavior, consisting of grooming, rearing and consistent locomotion,
that was lost due to DA depletion. Similarly, D2 receptor agonists (RU 24213 and lisuride)
could restore locomotor activity in reserpine-pretreated mice. Also, motor behavior stimulated
by a D2 receptor agonist in reserpine-treated mice cannot be blocked by a heterotypic (D1)
antagonist. This led to the conclusion that prior DA depletion elicits a change in the relationship
between D1 and D2 receptor such that they each function independently of one another (Starr,
Starr, & Kilpatrick, 1987).
In 6-OHDA treated rats, the death of the dopaminergic neurons along with the depletion
of endogenous DA liberates D1 and D2 receptors from their independence with each other and
induces profound receptor supersensitivity. After a unilateral 6-OHDA lesion, independent
stimulation of D1 or D2 receptors will result in rotation away from the lesioned side (Arnt and
Hyttel, 1984) indicative of an asymmetric breakdown in D1/D2 synergism. LaHoste and
Marshall (1992) performed bilateral 6-OHDA lesions on rats and found that there was increase in
locomotor activity and motor stereotypy in response to D1 or D2 agonist alone. Similar to what
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occurs following destruction of DA neurons by 6-OHDA, depletion of synaptic DA by
administration of reserpine, which disrupts vesicular storage of monoamines, also results in D1
and D2 independence and supersensitivity (LaHoste & Marshall, 1993).

D1/D2 Receptor Co-Localization
What is the mechanism of D1/D2 receptor synergism? One could hypothesize very
different mechanisms depending on whether D1 and D2 receptors are located on the same neuron
or on distinct neurons. This has been an issue of debate. In situ hybridization histochemistry
studies show that the majority of D1 and D2 receptors are located on separate pathways. Most
striatonigral pathway neurons (which project to the SNr and constitute the “direct pathway”)
express D1 receptor mRNA as well as dynorphin and substance P mRNA, but not D2 mRNA.
Most striatopallidal pathway neurons (which project to the globus pallidus and constitute the
“indirect pathway”) neurons expressed both D2 receptor mRNA and enkephalin mRNA but not
D1, dynorphin, or substance P mRNA (Gerfen, Engber, Mahan, Susel, Chase, Monsma et al.
1990). Thus, the vast majority of striatal neurons express only one DA receptor subtype.
Investigators using single-cell reverse-transcription polymerase chain reaction (RT-PCR)
claim that D1 and D2 mRNA are co-expressed in half of the medium spiny striatal neurons
(Surmeier, Song, & Yan, 1996). One drawback to this technique is that multiple rounds of PCR
are performed, resulting in an amplification factor in the billions. However, when a single round
of PCR was conducted versus multiple rounds, there was very little co-localization seen between
D1 and D2 receptors. These results were similar to the results presented above by Gerfen using
in situ hybridization.
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Based on these results, Surmeier and colleagues raised the question that behavioral
synergism may be due to interactions between D1 and D3, D1 and D4 receptors or D2 and D5
receptors located on the same neuron. LaHoste, Henry, & Marshall (2000) used newly
developed antagonists that were selective for D2, D3, and D4 receptor subtypes to test this
hypothesis. They found that specific D2 antagonists, but not D3 or D4 antagonists, were able to
block DA agonist-induced expression of c-fos, a marker of D1/D2 synergism (see above).
Research by both proponents of D1/D2 co-localization and D1/D2 segregation, however,
seems to show that the majority of D1 and D2 receptors are located on separate neurons and that
these neurons belong to separate pathways that project to different areas of the basal ganglia.
Thus, there must be some type of interneuronal communication between the two types of
receptors that can explain D1/D2 synergism.

Interneuronal Communication
The most typical form of communication between neurons is through the synapse by
action potential-induced release of neurotransmitter substance. If D1 and D2 receptors are on
separate neurons and communicate using action potentials to effect D1/D2 synergism, then
blockade of action potentials should block D1/D2 synergism. LaHoste et al. (2000) administered
the fast sodium channel blocker tetrodotoxin (TTX) intrastriatally to rats. While this blocked
action potentials, D1/D2 synergism remained intact (as seen indicated by c-fos expression).
Since D1/D2 synergism occurs under conditions in which separate D1- and D2expressing neurons cannot communicate through action potentials, we offer an alternative
hypothesis involving electrotonic communicating via gap junctions.
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Electrotonic Coupling
Electrotonic coupling takes place among neurons via gap junctions. Gap junctions
provide neurons with a means of intercellular communication in the retina and several brain
nuclei in mammals including the striatum (Cepeda, Walsh, Hull, Buchwald, &Levine, 1989;
Grace and Bunney 1983: Lasater and Dowling 1985). Furthermore, several studies have shown
that DA acts to gate gap junction channels in the retina and striatum. For example, at the
beginning of the light cycle, DA is released from the amacrine cells of the retina and acts on D1
receptors there to suppress electrotonic transmission between adjacent horizontal cells (Lasater
and Dowling 1985; McMahon, Knapp, & Dowling, 1989).
Histochemically, coupling can also be illustrated using gap junction-permeable Lucifer
Yellow dye, which can be injected into individual cells. If the injected cell is coupled to another,
the dye will pass through the gap junction and fill the adjoining cell. This form of labeling is a
reliable indicator of electrotonic coupling between neurons in the brain (Grace and Bunney,
1983). Research using the Lucifer Yellow dye has shown coupling between neurons in the
ventral striatum (nucleus accumbens) that is modulated by DA. Stimulation of D1 receptors led
to a decrease in coupling between neurons, whereas stimulation of D2 receptors did not change
the coupling between cells from control levels (O’Donnell and Grace, 1993). Both electrolytic
and neurochemical DA-depleting lesions in the dorsal striatum, which result in the breakdown of
D1/D2 synergism and agonist supersensitivity, resulted in increased dye coupling between
striatal neurons (Cepeda et al., 1989).
Dopaminergic neurons in the SNc have been shown to be electotonically coupled to one
another (Vandecasteele, Glowinski, & Venance, 2005). Furthermore, the firing frequency of
coupled DA neurons there is modulated by gap junctions. Also, when compared with chemical
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synapses it appears that electrical synapses appear to have a greater impact in fast
communication between DA neurons.
Previous research in our laboratory has investigated the role of Cx32 in D1/D2 synergism
(Cline, 2000; McKenna, 2004). At the time that work was begun, Cx32 was the only known
connexin present in neurons. Results from this work did not indicate that Cx32 was involved in
D1/D2 synergism. Since then, Cx36 was cloned and shown to be present to a substantial degree
in neurons. Cx36 is located throughout the brain including the dorsal and ventral striatum
(Condorelli et al., 2000). Since, as stated earlier, the majority of D1 and D2 receptors are located
on separate neurons, and since D1/D2 synergism occurs in the absence of action potentials, the
present study aimed to elucidate the role of Cx36-constituted gap junctions in D1/D2 synergism.

Hypotheses and Rationale
Research suggests that connexins might play a role in D1/D2 synergism in the striatum.
Since Cx36 is known to be present in the striatum, and since depletion of DA leads to a
breakdown in D1/D2 synergism and an increase in gap junction dye coupling, we reasoned that
mice that have been engineered to be incapable of expressing Cx36 protein should behave
differently than their wild-type littermates on striatally-mediated behavioral tests after separate
and concomitant administration of selective D1 and D2 agonists.

Hypothesis 1: Genetically engineered mice that differ in their ability to produce Cx36
protein will differ with respect to stereotyped motor behavior following separate or combined
agonist stimulation of D1 and D2 receptors.
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Hypothesis 2: Genetically engineered mice that differ in their ability to produce Cx36
protein will differ with respect to stereotyped motor behavior following separate or combined
agonist stimulation of D1 and D2 receptors after reserpine pre-treatment.
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Methods

Animals
Mice were bred in the University of New Orleans Department of Psychology rodent
colony from male and female breeders kindly donated by Dr. David L. Paul (Harvard
University). Original founder mice had been generated by inserting two reporter genes (Egalacotosidase and placental alkaline phosphatase) into the Cx36 coding region by means of
homologous recombination (Deans, Gibson, Sellitto, Connors, & Paul, 2001). This resulted in
mice whose Cx36 gene was “knocked-out.” The breeding of heterozygous male and female
Cx36 mice results in three genotypes, two homozygous and one heterozygous. The homozygous
genotypes are: “wild type” (WT), in which both Cx36 alleles are normal, and “knockout” (KO)
in which both Cx36 alleles have been altered to prevent transcription. Heterozygotes (Het) have
one mutated and one normal allele.
From the resulting breeding colony, adult male mice, weighing 20-30g were chosen for
used in the present study. Animals were kept in same-sex cages in groups of 6-10 with free
access to food and water. Artificial lighting was provided from 0700 to 1900h. All mice were
maintained and used in accordance with the guidelines for animal care and experimentation
established by the National Institutes of Health and the University of New Orleans Institutional
Animal Care and Use Committee (approved protocol #070).

Genotyping
On postnatal day (P) 30-35, mouse pups were genotyped using genomic DNA purified
from tail biopsies obtained under general anesthesia (2% tribromoethanol, 0.10-0.15 ml/10 gram
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body weight, i.p.). Biopsy tissue was digested overnight at 55oC in proteinase K. After
centrifugation, isopropanol was added to the supernatant to precipitate high molecular weight
genomic DNA. Genomic DNA was amplified using PCR: 1) Cx36 genotyping solution was
made of the following: 10X buffer, 25mM Mg++, 2.5 mM dNTPs, a 3’ primer that is common to
both WT and KO alleles, a 5’ WT-specific primer, and a 5’ KO-specific primer; 2) 28Pl of the
Cx36 genotyping solution was distributed to individual tubes; 3) 1-3Pg of genomic DNA from
each mouse was added to each tube, along with 0.5Pl Taq polymerase; 4) the tubes were then
placed in a thermocycler (for 30 cycles) to amplify the DNA. After amplification, the DNA was
analyzed using electrophoresis in a 1% agarose gel.

Paradigm for Assessing D1/D2 Synergism and its Breakdown
Stereotyped motor behavior in rodents is elicited by high doses of DA agonists acting in
the dorsal striatum. In normal animals, this behavior is only elicited following combined
stimulation of D1- and D2-type receptors. By assessing the ability of separate or combined
stimulation of D1 and D2 receptors to elicit stereotypy in mice genetically engineered to express
different amounts of Cx36, we can test the hypothesis that this protein plays a role in the
maintenance of D1/D2 synergism (Hypothesis 1). Following daily reserpine treatments, the
same striatally-mediated stereotyped behaviors that normally require concomitant D1/D2
stimulation can now be elicited independently by either D1 or D2 agonist stimulation. By
assessing the ability of independent stimulation of D1 or D2 receptors to elicit stereotypy in
reserpine-pretreated Cx36 transgenic mice, we can test the hypothesis that this protein plays a
role in the breakdown of D1/D2 synergism (Hypothesis 2).
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Drug Treatments
Experiment 1. To investigate D1/D2 synergism, we gave Cx36 KO (n = 8), WT (n = 7),
and Het mice (n = 8) drug treatments that resulted in agonist stimulation of (a) D1 receptors, (b)
D2 receptors, (c) D1 and D2 receptors, or (d) neither D1 nor D2 receptors. Each mouse received
each of the drug treatments in counterbalanced order as determined by a Latin square (see Table
1). Drug treatments were separated by 72-96h intervals.

Table 1. Receptor(s) Stimulated
Test Day
Order

1

2

3

4

A

None

D1+D2

D2

D1

B

D1

D2

None

D1+D2

C

D2

D1

D1+D2

None

D

D1+D2

none

D1

D2

D1 and D2 receptors were stimulated by the mixed D1/D2 agonist apomorphine (3.0
mg/kg, i.p.). Selective agonist stimulation of individual receptor subtypes was achieved by prior
(30 min.) selective blockade of the heterotypic receptor. Thus, D1 receptors were stimulated by
apomorphine preceded by the selective D2 antagonist eticlopride (0.3 mg/kg, i.p.); D2 receptors
were stimulated by apomorphine preceded by the selective D1 antagonist SCH 23390 (0.1
mg/kg, i.p.). Details of acute drug treatments are given in Table 2. Stereotyped motor behavior
was recorded for one hour following each drug treatment (see below).
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Table 2. Time Course of Acute Drug Treatments
Receptor(s)

Time (min.)

stimulated

0

30

none

vehicle

vehicle

D1

eticlopride

apomorphine

D2

SCH 23390

apomorphine

D1+D2

vehicle

apomorphine

Experiment 2. To induce the breakdown in D1/D2 synergism, we gave mice reserpine (1
mg/kg, i.p.) once daily. DA depletion was assessed 24 hrs. after reserpine injection using
catalepsy as the dependent variable. Forelimbs were placed on a horizontal bar and the latency
to step down was recorded. If step-down latency was >180 sec., agonist testing followed; if
latency was <180 sec., mice were returned their home cages and given an additional reserpine
injection on the following day. Mice reaching a criterion of 180 seconds of catalepsy were tested
for motor stereotypy in response to selective D1 or D2 activation. Each mouse was tested under
each agonist condition (as described above) by testing on successive days, the order of which
was counterbalanced within each genotype (WT: n = 5; Het: n = 8; KO: n = 9). Stereotyped
motor behavior was recorded for one hour following stimulation of each receptor type (see
below).

Behavioral Assay of D1/D2 Synergism
Mice were tested for motor behavior following each of the drug treatments. Each mouse
was placed in a plastic cylinder (measuring 30 cm high, 16cm diameter) for one hour prior to
drug treatment. The animals’ behavior was recorded with a Sony digital video camera.

15

Stereotyped motor behavior was observed for 30 seconds every 5 minutes beginning 5 minutes
prior to any drug injection and continuing until one hour after the second drug (agonist) had been
administered. Behavior was rated using a scale of 0-5 that was modified for mice from LaHoste
and Marshall (1993), and represents species-specific stereotypies elicited by increasing doses of
DA agonists (Table 3). In addition, grooming behavior was quantified as the amount of time
spent grooming during each 30-second observation period.

Table 3. Stereotyped Behavior Rating Scale
Score Behavior
0

still

1

grooming

2

discontinuous stereotyped behavior (sniffing interrupted by grooming)

3

continuous unfocused stereotypy (sniffing/licking/chewing without spatial focusing)

4

continuous focused sniffing (sniffing that takes place at only one particular site)

5

continuous focused oral stereotypy (licking/chewing that takes place in one site)

Data Analysis
Behavior scores were initially subjected to a mixed-design three-way analysis of
variance (ANOVA) with one between-subjects factor (Genotype) and two within-subjects factors
(Drug Treatment and Time). Significant main effects were further analyzed by Newman-Keuls
post-hoc tests. In some cases, data from each animal were averaged over Time, thus eliminating
this variable and avoiding the often difficult interpretation of higher-order interactions.
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Results

The Role of Connexin36 in D1/D2 Synergism
To investigate potential behavioral differences between genetically engineered mice that
differ in their ability to produce Cx36 protein, we measured stereotyped motor behavior
following different drug treatments that stimulated D1 and D2 receptors either separately or in
combination. The results show that sustained motor stereotypy is observed only following
combined stimulation of both D1 and D2 receptors, indicating D1/D2 synergism (Fig. 1).
Stimulation of D2 receptors alone elicited an early burst of stereotypy that was quickly
suppressed, an effect that is consistently observed in rats (e.g., LaHoste & Marshall, 1992).

5

agonist
or
saline

Stereotypy score

4

saline
D1
D2
D1/D2

3

2

1

0
-10

0

10

20

30

40

50

60

min

Figure 1. Mean stereotypy scores following separate or combined stimulation of D1 and
D2 receptors illustrate D1/D2 synergism. n = 21-23. For description of stereotypy rating
scale in this and subsequent figures, see Methods.
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5

Knockout

Heterozygote

Wild-type

stereotypy score

4

3

2

1

0

saline D1

D2

D1/D2

saline D1

D2

D1/D2

saline

D1

D2

D1/D2

Figure 2. Mean stereotypy scores averaged over the 60-minute post-agonist time interval
and grouped by genotype for all drug treatments. n = 7-8. Scores for the combined D1/D2
treatment are significantly higher (p<.001) than for any of the other treatments, which do not
differ significantly from each other. The genotypes do not differ significantly.

The presence or absence of Cx36 did not affect the behavioral expression of D1/D2
synergism (Fig. 2). A 2-way ANOVA with one repeated measure (Drug Treatment) and one
between-subjects measure (Genotype) revealed a significant main effect for Drug Treatment
(F3,60 = 245.1, p<.001) but no significant main effect for Genotype (F2,20 =2.1, ns) and no
Drug Genotype interaction (F6,60 = 0.8, ns). Post hoc tests on the Drug Treatment effect showed
that the combined agonist group differed significantly from all other agonist or vehicle
treatments (Fig. 3). Therefore, D1 and D2 receptors synergize at the behavioral level in a normal
manner in mice lacking Cx36.
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Figure 3. Mean stereotypy scores collapsed across genotypes and averaged over time.
Combined D1/D2 treatment is significantly different from all other treatments. Brackets
indicate significant differences as determined by Newman-Keuls post hoc tests, p<.01.
n = 21-23.

The Role of Connexin36 in D1 Receptor–mediated Behavior
To further analyze the role of Cx36 in behaviors that are modulated by DA receptors, we
examined differences between genotypes in D1 agonist-stimulated grooming, a behavior that
does not require concomitant stimulation of D2 receptors (LaHoste & Marshall, 1992). Data
were analyzed by a 2-way ANOVA with one repeated measure (Time: pre- vs. post-agonist) and
one between-subjects factor (Genotype). As shown in Figure 4, D1 receptor stimulation elicited
grooming behavior as indicated by a significant main effect for Time (F1,20 = 58.9, p<.001).
There was no main effect for Genotype (F2,20 =0.4) nor significant Genotype X Time interaction.
Therefore, D1 receptor-stimulated grooming is normal in mice lacking Cx36.
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Figure 4. Mean grooming scores (number of seconds spent grooming per 30-sec. observation
period) grouped by genotype and averaged across the 15-min. time period just prior to agonist
injection and the 1-h time period following agonist injection. n = 7-8. D1 stimulation elicited
significant grooming (p<.001). The genotypes do not differ significantly.

The Role of Connexin36 in D2 Receptor-mediated Behavior
As indicated above, stimulation of D2 receptors alone reliably elicits an early D1independent burst of stereotypy that quickly subsides to baseline levels by 20 minutes postagonist (see Fig. 1). To determine if there were differences between genotypes in D2 receptor
stimulation alone we re-examined the stereotypy scores for the first 15 minutes after saline or
selective stimulation of D2 receptors (D1 antagonist + apomorphine). A 2-way ANOVA
revealed a significant Drug effect (F1,20 = 38.0, p<.001) but no Genotype effect (F1,20 = 1.3, ns)
and no Drug X

Genotype interaction (F2,20 = 2.5, ns) (Fig. 5). Therefore, the brief D2-
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stimulated behavioral activation that is independent of D1 receptors is normal in mice lacking
Cx36.
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Figure 5. Mean stereotypy scores for the first 15 min. after apomorphine injection
(following pre-treatment with a D1 antagonist) or following saline. n = 7-8. Selective
D2 receptor activation produced a significant, short-lasting stereotypy (p<.001) that did
not differ across genotypes.

The Role of Connexin36 in the Breakdown of D1/D2 Synergism
To study the role of Cx36 in the breakdown of D1/D2 synergism, we administered the
DA-depleting drug reserpine, a treatment that is known to cause a breakdown in D1/D2
synergism in normal rodents. Behavioral results following separate D1 or D2 receptor
stimulation are presented in Figure 6. The results show D1 and D2 receptor independence in
reserpine-pretreated mice. That is, mice showed sustained and robust motor stereotypy
following selective stimulation of either D1 or D2 receptors.
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Figure 6. Mean stereotypy scores plotted across time in reserpine-treated mice reveal
D1 and D2 independence. n = 22.

To assess this breakdown in D1/D2 synergism and its possible modulation by Cx36, we
compared the behavioral responses of reserpine- and non-pretreated mice as a function of
genotype (Fig. 7). Data were averaged over the one-hour post-agonist period and subjected to a
3-way ANOVA with one repeated measure (Drug Treatment: D1 vs. D2 stimulation) and two
between-subjects factors (Pretreatment: reserpine or no reserpine; and Genotype). There were
significant main effects for Drug Treatment (F1,39 = 16.5, p<.001) and Pretreatment (F1,39 = 72.0,
p<.001), but not Genotype (F2,39 = 0.04, ns). However, there was a highly significant Drug
X Genotype interaction (F2,39 = 6.4, p=0.004); no other interactions were significant.
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Figure 7. Mean stereotypy scores following selective D1 or D2 receptor stimulation in
non-pretreated and reserpine-pretreated mice, averaged across the 1 h post-agonist time
period. n = 5-9. Reserpine pretreatment caused a >3-fold increase in stereotypy scores.
Genotypes did not differ.

To address the Drug X Genotype interaction we compared genotypes within drug
treatments but found no significant differences across genotype (Fig. 8). The significant Drug X
Genotype interaction likely reflects the fact that the pattern of mean differences across genotype
differs for D1- and D2-stimulated behavior. In general, reserpine greatly potentiates the
stereotypic response to selective D1 or D2 stimulation, but does so equally for D1 and D2
receptors and equally for all genotypes.
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Figure 8. Post hoc analysis of data in Fig. 6. Mean stereotypy scores are collapsed
across pretreatment for illustration of the significant Genotype ✕ Drug interaction. There
are no significant post hoc differences within either drug treatment. n = 13-16.

Catalepsy and Connexin36
While giving reserpine injections to the mice it was noticed that there were differences
among the three genotypes in their response to the drug. Specifically, it was observed that Cx36
KO mice required much more reserpine to reach the criterion of 180 seconds of catalepsy
compared to WT mice, while Hets required an intermediate amount. These differences were
quantified, and are depicted in Figures 9 and 10. With respect to the number of daily injections
of reserpine it took to induce 180 seconds of catalepsy, a 1-way ANOVA indicated a significant
main effect for Genotype (F2,18 = 39.2, p<.001). Post hoc tests indicated that all groups were
different from each other (Fig. 9) with the WT mice requiring the fewest number of injections
and KO mice requiring the most. When cumulative dose-response data were analyzed using the
Allfit computer program, the ED50s for WT, Het, and KO mice were all significantly different
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from each other (p<.001, Fig. 10). These data demonstrate an unexpected finding, namely that
loss of Cx36 leads to resistance to the cataleptic effects of reserpine in a gene dosage-dependent
manner.
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Figure 9. Mean number of 1 mg/kg reserpine injections required to reach 180 s of
catalepsy. Brackets indicate significant differences as revealed by Newman-Keuls post
hoc tests, p<.001. n = 6-9. All genotypes differ significantly, indicating a Cx36 gene
dosage-dependent sensitivity to reserpine.
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Figure 10. Computer-generated sigmoidal best-fit curves for mean catalepsy scores.
Calculated ED50s: wild-type, 1.2 mg/kg,; heterozygote, 2.8 mg/kg,; knockout, 4.0 mg/kg.
n= 6-9. Increasing loss of Cx36 leads to lower sensitivity to reserpine.
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7

Discussion

Much research over the past two decades has shown that many of the behavioral,
physiological and cellular effects of DA require concomitant stimulation of D1 and D2 receptors
to be manifested, a phenomenon known as D1/D2 synergism. The purpose of this study was to
investigate a possible mechanism for D1/D2 synergism and its breakdown. Previous findings
suggested that synergism could not be explained by either receptor co-localization within the
same neuron or by classical interneuronal communication via action potentials. By using mice
with targeted disruptions to the connexin gene Cx36, the present thesis investigated the
possibility that electrotonic coupling between neurons via gap junctions plays a role in D1/D2
synergism.
The main findings of the present research suggest that Cx36 does not play a role in
D1/D2 synergism or its breakdown. Synergism was assessed by testing for motor stereotypies
following strong activation of D1 and D2 receptors alone or in combination. Similar to what has
been found in rats, mice in the present study displayed intense, focused species-typical behaviors
(focused sniffing, chewing or licking) when given the mixed D1/D2 agonist apomorphine.
These agonist-elicited behaviors could be blocked by either a selective D1 or D2 antagonist,
indicating that co-stimulation of the two receptor subtypes was required (Figs. 1 and 2). Of
particular importance for the present thesis, this same pattern of response, demonstrating intact
D1/D2 synergism, was observed in mice of all genotypes (Fig. 2). Thus, the degree to which
Cx36 protein was present or absent had no effect on the outcome.
There are some exceptions to the rule that DA-stimulated behavior requires concomitant
stimulation of D1 and D2 receptors. For example, D1 stimulation elicits grooming behavior that
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is not blocked by a D2 antagonist. In addition, a very reliable finding in the primary behavioral
paradigm used here is that there is an early component of D2-elicited stereotypy that is not
blocked by a D1 antagonist (see, e.g., Fig. 1). Since the presence or absence of Cx36 had no
effect on behaviors requiring co-stimulation, we asked whether independently mediated D1 or
D2 behaviors differed across genotypes. As expected, independent activation of D1 receptors
(apomorphine in the presence of D2 blockade) elicited grooming behavior; however, this effect
was observed to the same degree in all genotypes (Fig. 4). When we re-examined the transient
activation of motor stereotypy that is mediated independently by D2 receptors (apomorphine in
the presence of D1 blockade), we found that this activation was present to similar degrees in all
genotypes (Fig. 5).
Depletion of DA by the drug reserpine causes a breakdown in D1/D2 synergism. That is,
the same behaviors that normally require co-activation of D1 and D2 receptors can now be
elicited independently by agonist stimulation of either receptor subtype. When these transgenic
mice in the present study were administered reserpine they showed D1 and D2 receptor
independence (Fig. 6). In comparing the reserpine treated mice to the intact mice there was a
three-fold increase in stereotypy scores in D1 and D2 receptor stimulation alone (Fig. 7).
Nonetheless, there were no genotype differences in these results. Thus, Cx36 does not appear to
be involved in the breakdown of D1/D2 synergism. There was one interesting observation that
was made between the genotypes and that was their cataleptic response to the drug reserpine
(Fig. 9 and 10), which was significant for each of the genotypes (p < .001). The WT mice
required less cumulative reserpine to reach 180 seconds of catalepsy and the KO mice required
more reserpine to reach the same criterion. Thus, the absence of Cx36 appears to have some
protective effect against the cataleptic action of reserpine.
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Why was there no effect of the loss of Cx36?
The standard method of generating knockout mice results in the loss of the “knockedout” gene from the very beginning of development. Thus, interpretation of the results of studies
using such mice must take into consideration the possibility of developmental compensation.
There is evidence to suggest that this may incur in Cx36 knockout mice. In the inferior olive
widespread electrical coupling gives rise to rhythmic subthreshold oscillations in membrane
potential. Although electrotonic coupling in this nucleus is mediated almost exclusively by
Cx36-constituted gap junctions, Long, Deans, Paul, & Connors (2002) found that these olivary
oscillations were nonetheless preserved in Cx36 knockout mice. De Zeeuw, Chorev, Devor,
Manor, Van Der Giessen, De Jeu et al. (2003) found that olivary neurons in the knockout mice
had both structural and electrophysiological compensations that allowed normal oscillations that
were no different from those of wild-type mice. Could there be some type of compensation that
is taking place in our Cx36 mice that could explain our behavioral results? Perhaps D1/D2
synergism is normally mediated by Cx36, but the loss of this protein developmentally leads to
compensatory structural or functional changes—perhaps the increased expression of other
connexins—resulting in the appearance of normal behavior. We found that there are differences
between WT and KO mice with respect to sensitivity to reserpine. Perhaps the compensatory
changes that normalize DA-mediated behavior also lead to a resistance to reserpine.
There is also the possibility that, while electrotonic coupling via gap junctions may be
involved in D1/D2 interactions, Cx36 may not be the critical connexin. Although few other
known connexins are likely candidates, this is a large protein family with possibly as yet
undiscovered members. Finally, one must consider the possibility that the small number of
medium spiny neurons with co-localized D1 and D2 receptors mediate D1/D2 synergism. A
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transgenic method that could test this hypothesis would be a Cre-lox system in which D1
receptors were conditionally knocked-out only in cells that also expressed D2 receptors (or vice
versa).
In order to address the genotype differences in the response to the drug reserpine we
would have to look at a number of issues. First, are there differences in how the drug reserpine
is metabolized by the mice? This could be investigated by examining brain tissue reserpine levels
using mass spectrometry. If there were differences found in the amount of striatal reserpine, then
the Cx36 knockout mouse could serve as a model for metabolic resistance to reserpine. Second,
are there differences in how dopamine is depleted due to reserpine in these mice? One could
perform HPLC (High Performance Liquid Chromatograph) to assess the amount of dopamine
that is present in brain tissue of the mice after reserpine treatment. If there were differences
found in the amount of striatal dopamine then the Cx36 knockout mouse could serve as a model
for neurochemical resistance to dopamine depleting agents. If there were no genotype
differences in the amount of striatal reserpine or dopamine, then the Cx36 knockout mouse could
serve as a model for behavioral resistance to dopamine depletion. These could prove to be
useful models in research on Parkinson’s disease, the symptoms of which are due to depletion of
striatal dopamine.
In summary, the present thesis found DA D1/D2 synergism to be intact in mice with
targeted deletions of Cx36 genes. Nor was the induced breakdown in D1/D2 synergism affected
by the absence of Cx36 gene. However, Cx36 does play a role in the action of the drug
reserpine. This difference could be due to any number of causes including structural or
electrophysiological compensations, gene regulation or reserpine metabolism.
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